Parietaria judaica-specific immunoglobulin E (Par j-sIgE) (Par j-sIgE)

Parietaria judaica-specific IgE antibodies are specialized immunoglobulins produced by the immune system in response to allergens from the Parietaria judaica plant, a significant source of aeroallergens in Mediterranean climates (D'Amato et al., 2007, Allergy). These antibodies are the primary mediators of Type I hypersensitivity reactions; they bind to the surface of mast cells and basophils via the high-affinity FcεRI receptor (Gould & Sutton, 2008, Nature Reviews Immunology). Upon subsequent exposure to Parietaria pollen allergens, such as the major allergens Par j 1 or Par j 2, the allergens cross-link the bound IgE, triggering the release of histamine and other inflammatory mediators that cause symptoms of allergic rhinitis and asthma (Ayuso et al., 1993, International Archives of Allergy and Immunology). In clinical practice, these antibodies serve as both diagnostic biomarkers and indirect targets for therapy. Treatments include omalizumab, which neutralizes circulating IgE regardless of specificity (FDA Label, Xolair), and allergen-specific immunotherapy (AIT), which aims to modulate the immune response to reduce the levels or effector functions of these specific antibodies (Alvaro-Lozano et al., 2020, Pediatric Allergy and Immunology). Monitoring the levels of these specific antibodies is crucial for diagnosing sensitization and assessing the efficacy of desensitization treatments.

Other names

Pellitory-specific IgEAnti-Parietaria judaica IgEParietaria-specific IgEAnti-Par j IgE

Anti-IgE antibodies like omalizumab bind to the Cε3 domain of circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils (Xolair Prescribing Information). Allergen immunotherapy (AIT) works by inducing peripheral T-cell tolerance and promoting the production of 'blocking' antibodies, such as IgG4, that compete with IgE for allergen binding, thereby preventing IgE-mediated mast cell degranulation (Shamji & Durham, 2017, Journal of Allergy and Clinical Immunology).